Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Esthetician's Alliance of America offers guidance at the International Esthetics, Cosmetics, and Spa Conference (IECSC Las Vegas) on Protecting Your Practice


News provided by

Esthetician's Alliance of America

Jun 21, 2024, 13:40 ET

Share this article

Share toX

Share this article

Share toX

The Esthetician's Alliance of America warns of fake Botox
The Esthetician's Alliance of America warns of fake Botox

The Esthetician's Alliance of America issues an advisory with guidance for medical and esthetic industry professionals during the International Esthetics, Cosmetics, and Spa Conference (IECSC Las Vegas). The organization provides the FDA's counterfeit botox alert and the legal risks of cosmetic product origins.

LAS VEGAS, June 21, 2024 /PRNewswire-PRWeb/ -- The Esthetician's Alliance of America issues an advisory with guidance for medical and esthetic industry professionals in advance of the International Esthetics, Cosmetics, & Spa Conference (IECSC Las Vegas), presented by American Spa. The organization highlights the FDA's counterfeit Botox alert and legal risks of cosmetic product origins.

On May 1, 2024, the FDA issued a warning to medical and aesthetic industry professionals regarding the presence of counterfeit Botox in both licensed and unlicensed settings. This advisory underscores the importance of vigilance in sourcing cosmetic and medical products to ensure the safety and legality of treatments.

When the FDA's Cosmetic Direct tool is published, the Esthetician's Alliance of America strongly urges all estheticians to use this tool. Proper verification through Cosmetic Direct will ensure that licensees are working within their scope of practice and are using products classified as cosmetics.

Post this

The medical aesthetic industry is experiencing significant growth, leading to increased demand for products such as Botox, hyaluronic acid fillers, fat dissolvers, and chemical peels. This demand has unfortunately opened the door for unauthorized distributors to market these products, often under identical packaging or as off-brand alternatives sourced from overseas manufacturers. These products pose significant risks to both providers and patients.

Federal law prohibits the importation of non-FDA-approved drugs. Aesthetic professionals must understand that the legality of purchasing products for professional use heavily depends on how the FDA classifies these products, determining whether a product is considered a drug or a cosmetic.

The aesthetic industry has long faced ambiguity regarding what is technically considered a cosmetic versus a drug. Without FDA approval or registration, an aesthetic treatment product marketed and sold for professional use might fall into the category of a drug, despite claims of being a cosmetic. This distinction is vital for ensuring compliance and avoiding legal pitfalls.

The FDA does not strictly regulate or require testing on products considered cosmetics, often allowing manufacturers to import products under cosmetic labeling. However, ingredients or concentrations might be mislabeled and categorically considered drugs, thus violating federal law.

In an aesthetic professional setting, it is essential for individuals responsible for procuring cosmetic or aesthetic medical products to verify the legitimacy of distributors through the manufacturer. This verification process should ensure that the products are either voluntarily registered in the FDA's cosmetic databases, The International Nomenclature of Cosmetic Ingredients (INCI), or have active FDA approval and registration.

Using unverified cosmetics on clients can pose significant risks, akin to those associated with counterfeit or unregistered medical drugs like Botox. This is particularly concerning for unregistered cosmetic products, as the ambiguity of ingredients or concentration levels claiming to be cosmetic might be classified as drugs by the FDA, causing an esthetician to illegally practice medicine. Understanding how the FDA registers and classifies cosmetics is crucial to avoid misbranded products.

In 2022, it was announced that the Voluntary Cosmetic Registration Program (VCRP) would be replaced by the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Starting July 1, 2024, estheticians will need to verify products as cosmetics suitable for use in their scope of practice through the new Cosmetic Direct database. This modernization aims to mitigate the risks or uncertainty regarding cosmetic classifications, a common challenge for Cosmetology State Boards.

Sourcing unverified cosmetic products from overseas manufacturers could potentially violate FDA regulations. If these products contain certain concentrations of ingredients considered drugs by the FDA, they should require a prescription, leading to serious repercussions, including the removal of the esthetician's license. Ensuring compliance with FDA standards is crucial for maintaining professional integrity and client safety.

"When the FDA's Cosmetic Direct tool is published, the Estheticians Alliance of America strongly urges all estheticians to use this tool. Proper verification through Cosmetic Direct ensures that licensees are working within their scope of practice and using products classified as cosmetics," advises the Estheticians Alliance of America. https://www.fda.gov/drugs/information-health-care-professionals-drugs/know-your-source-protecting-patients-unsafe-drugs

For medical professionals, purchasing Botox or other drugs from legitimate overseas sources to save money can expose them to substantial legal risks. This practice, known as "parallel importation," involves buying pharmaceuticals from countries with regulated drug prices and selling them in the U.S. at lower costs. However, importing drugs not explicitly intended for U.S. use remains illegal.

  • In June 2018, Oregon-based physician Brenda Roberts faced the revocation of her medical license for purchasing Botox from overseas sources. Despite the drugs being legitimate, their use in the U.S. was unauthorized. Proper authorization is required to ensure drugs like Botox meet the United States' standards for safety and efficacy.
  • On April 23, 2024, the CDC released a public notice on the adverse effects and risks of mishandled and counterfeit Botox, reporting cases of botulism and hospitalizations linked to improper procurement and administration.
  • In 2015, SB Medical Inc. and TC Medical Group, based in Toronto, Canada, and St. Michael, Barbados respectively, were found guilty of illegally distributing misbranded pharmaceuticals in the U.S., including Botox and Juvaderm. This resulted in substantial fines and forfeitures amounting to $75 million in total. These companies were involved in a multi-year conspiracy to smuggle and sell these misbranded drugs, generating over $33 million in illegal proceeds. The misbranded pharmaceuticals were sourced from various foreign countries, including India, Turkey, France, and Italy, and included a range of products from orthopedic injections to oncology drugs. David E. Burke, one of the individuals implicated in this conspiracy and known to have used the alias "David Johnson," continues to operate a U.S. aesthetic distribution company named Bioskin Aesthetics despite these past controversies. https://www.justice.gov/usao-edva/pr/canadian-companies-fined-45-million-and-ordered-forfeit-additional-30-million-smuggling

The aesthetic industry must remain vigilant against the use of misbranded and counterfeit products to ensure the safety and efficacy of treatments. For estheticians, understanding the FDA's classification of cosmetics and utilizing resources like the upcoming Cosmetic Direct tool is crucial in maintaining compliance and protecting clients. Medical professionals must avoid the risks associated with the parallel importation of drugs, which can lead to severe legal and health consequences. By adhering to verified sources and maintaining rigorous standards, professionals in the aesthetic industry can uphold their commitment to client safety and professional integrity.

Learn more here: https://www.estheticiansallianceofamerica.com/post/the-fda-s-counterfeit-botox-warning-the-perils-of-off-brand-counterfeited-or-mishandled-aestheti

About Esthetician's Alliance of America

The goal of the Esthetician's Alliance of America is to empower estheticians with the knowledge they need to make informed purchase decisions on equipment and products. By providing access to reliable and up-to-date information, Estheticians Alliance aims to support the economic advancement of the professionals they serve. They strive to be a trusted resource that estheticians can rely on for guidance and clarity in their practice.

For more information, please contact:

Esthetician's Alliance of America

estheticiansallianceofamerica.com

[email protected]

512-827-8064

Media Contact

Taylor Cole, Esthetician's Alliance of America, 1 512-827-8064, [email protected], https://www.estheticiansallianceofamerica.com

SOURCE Esthetician's Alliance of America

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.